title: Pharmacokinetics of teicoplanin during cardiopulmonary bypass surgery.
abstract: Teicoplanin is a recently introduced long-acting glycopeptide antibiotic effective against Gram-positive aerobic and anaerobic bacteria. The effects of hypothermic extracorporeal circulation on teicoplanin serum pharmacokinetics have been studied in 18 patients undergoing open-heart surgery for coronary artery bypass graft or prosthetic cardiac valve insertion. The patients received a single 600 mg dose of teicoplanin by intravenous (i.v.) bolus (five cases) or by i.v. infusion over 20 min (13 cases) approximately 1 h before the anticipated skin incision and 2 h before the anticipated extracorporeal circulation. Serum drug concentrations were measured by a microbiological method using Bacillus subtilis ATCC 6633 as the test organism. Following i.v. bolus injection and i.v. infusion, teicoplanin levels in serum (mean +/- s.d.) were respectively 13.9 +/- 6.8 and 11.4 +/- 2.4 mg/l at the beginning of extracorporeal circulation, 8.8 +/- 3.5 and 10.2 +/- 2.3 mg/l at the end of this procedure and 2.8 +/- 0.6 and 2.9 +/- 1.0 mg/l at 24 h after surgery. Mean AUCs were 378.1 +/- 52.5 and 328.9 +/- 88.0/l.h and mean elimination half-life values were 27.9 +/- 12.7 and 30.3 +/- 11.0 h, respectively under the same conditions. These differences in plasma pharmacokinetic parameters were not significant. Teicoplanin pharmacokinetics in patients undergoing cardiopulmonary bypass surgery were similar to those observed in non-surgical patients with normal renal and hepatic function, confirming experimental evidence for lack of effects of extracorporeal circulation.
authors.affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Mini
authors.forename: T
authors.initials: T
authors.lastname: Mazzei
authors.forename: E F
authors.initials: EF
authors.lastname: Reali
authors.forename: A
authors.initials: A
authors.lastname: Novelli
authors.forename: P
authors.initials: P
authors.lastname: Periti
mesh_terms: D001424:Bacterial Infections / Q000517:prevention & control; D002315:Cardiopulmonary Bypass; D005260:Female; D006020:Glycopeptides / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D006350:Heart Valve Prosthesis; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011292:Premedication; D017334:Teicoplanin
chemical_list: D006020:Glycopeptides; D017334:Teicoplanin